SINGLE study (144-week data)

Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naïve Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial

Sharon Walmsley, MD, Axel Baumgarten, MD, Juan Berenguer, MD, Franco Felizarta, MD, Eric Florence, MD, Marie-Aude Khuong-Josses, MD, J. Michael Kilby, MD, Thomas Lutz, MD, Daniel Podzamczer, MD, Joaquin Portilla, MD, Norman Roth, MD, Deborah Wong, MSc, Catherine Granier, DESS, Brian Wynne, MD and Keith Pappa, PharmD

J Acquir Immune Defic Syndr 2015;70:515-519

Read the full publication

You will need to register to view the full publication.

Sign me up for an account

UK/DTGP/0037/16p Date of Prep March 2017